Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes.

Literature DB >> 22491454

The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes.

Matthieu Perreau¹, Hugh C Welles, Celine Pellaton, Bebeka Gjoksi, Lambert Potin, Ricardo Martin, Alexandre Harari, Andrew Bett, Danilo Casimiro, Jason Gall, Dan H Barouch, Eric J Kremer, Giuseppe Pantaleo.

Abstract

Adenovirus serotype 5 (Ad5) vectors and specific neutralizing antibodies (NAbs) generate immune complexes (ICs) which are potent inducers of dendritic cell (DC) maturation. Here we show that ICs generated with rare Ad vector serotypes, such as Ad26 and Ad35, which are lead candidates in HIV vaccine development, are poor inducers of DC maturation and that their potency in inducing DC maturation strongly correlated with the number of Toll-like receptor 9 (TLR9)-agonist motifs present in the Ad vector's genome. In addition, we showed that antihexon but not antifiber antibodies are responsible for the induction of Ad IC-mediated DC maturation.

Entities: Gene

Mesh：

Substances：

Year: 2012 PMID： 22491454 PMCID： PMC3372176 DOI： 10.1128/JVI.00123-12

Source DB: PubMed Journal: J Virol ISSN： 0022-538X Impact factor: 5.103

40 in total

1. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells.

Authors: Sonja I Gringhuis; Michiel van der Vlist; Linda M van den Berg; Jeroen den Dunnen; Manja Litjens; Teunis B H Geijtenbeek
Journal: Nat Immunol Date: 2010-04-04 Impact factor: 25.606

2. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.

Authors: Dan H Barouch; Sandra V Kik; Gerrit J Weverling; Rebecca Dilan; Sharon L King; Lori F Maxfield; Sarah Clark; David Ng'ang'a; Kara L Brandariz; Peter Abbink; Faruk Sinangil; Guy de Bruyn; Glenda E Gray; Surita Roux; Linda-Gail Bekker; Athmanundh Dilraj; Hannah Kibuuka; Merlin L Robb; Nelson L Michael; Omu Anzala; Pauli N Amornkul; Jill Gilmour; John Hural; Susan P Buchbinder; Michael S Seaman; Raphael Dolin; Lindsey R Baden; Angela Carville; Keith G Mansfield; Maria G Pau; Jaap Goudsmit
Journal: Vaccine Date: 2011-05-25 Impact factor: 3.641

3. Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation.

Authors: William C Adams; Cornelia Gujer; Gerald McInerney; Jason G D Gall; Constantinos Petrovas; Gunilla B Karlsson Hedestam; Richard A Koup; Karin Loré
Journal: Proc Natl Acad Sci U S A Date: 2011-04-18 Impact factor: 11.205

4. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.

Authors: Thomas W Geisbert; Michael Bailey; Lisa Hensley; Clement Asiedu; Joan Geisbert; Daphne Stanley; Anna Honko; Joshua Johnson; Sabue Mulangu; Maria Grazia Pau; Jerome Custers; Jort Vellinga; Jenny Hendriks; Peter Jahrling; Mario Roederer; Jaap Goudsmit; Richard Koup; Nancy J Sullivan
Journal: J Virol Date: 2011-02-16 Impact factor: 5.103

5. Interactions between human plasma components and a xenogenic adenovirus vector: reduced immunogenicity during gene transfer.

Authors: Matthieu Perreau; Marie-Christine Guérin; Christian Drouet; Eric J Kremer
Journal: Mol Ther Date: 2007-08-21 Impact factor: 11.454

6. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.

Authors: T Christopher Mast; Lisa Kierstead; Swati B Gupta; Alexander A Nikas; Esper G Kallas; Vladimir Novitsky; Bernard Mbewe; Punee Pitisuttithum; Mauro Schechter; Eftyhia Vardas; Nathan D Wolfe; Miguel Aste-Amezaga; Danilo R Casimiro; Paul Coplan; Walter L Straus; John W Shiver
Journal: Vaccine Date: 2009-11-17 Impact factor: 3.641

7. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

Authors: M Juliana McElrath; Stephen C De Rosa; Zoe Moodie; Sheri Dubey; Lisa Kierstead; Holly Janes; Olivier D Defawe; Donald K Carter; John Hural; Rama Akondy; Susan P Buchbinder; Michael N Robertson; Devan V Mehrotra; Steven G Self; Lawrence Corey; John W Shiver; Danilo R Casimiro
Journal: Lancet Date: 2008-11-13 Impact factor: 79.321

8. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors: Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal: Lancet Date: 2008-11-13 Impact factor: 79.321

9. Adenovirus serotype 5 hexon mediates liver gene transfer.

Authors: Simon N Waddington; John H McVey; David Bhella; Alan L Parker; Kristeen Barker; Hideko Atoda; Rebecca Pink; Suzanne M K Buckley; Jenny A Greig; Laura Denby; Jerome Custers; Takashi Morita; Ivo M B Francischetti; Robson Q Monteiro; Dan H Barouch; Nico van Rooijen; Claudio Napoli; Menzo J E Havenga; Stuart A Nicklin; Andrew H Baker
Journal: Cell Date: 2008-02-08 Impact factor: 41.582

10. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells.

Authors: Matthieu Perreau; Giuseppe Pantaleo; Eric J Kremer
Journal: J Exp Med Date: 2008-11-03 Impact factor: 14.307

18 in total

1. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

Authors: Kylie M Quinn; Daniel E Zak; Andreia Costa; Ayako Yamamoto; Kathrin Kastenmuller; Brenna J Hill; Geoffrey M Lynn; Patricia A Darrah; Ross W B Lindsay; Lingshu Wang; Cheng Cheng; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Emma Gostick; David A Price; Jason G D Gall; Mario Roederer; Alan Aderem; Robert A Seder
Journal: J Clin Invest Date: 2015-02-02 Impact factor: 14.808

2. Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity.

Authors: Jeffrey E Teigler; Jonathan C Kagan; Dan H Barouch
Journal: J Virol Date: 2014-07-02 Impact factor: 5.103

Review 3. Novel vaccine vectors for HIV-1.

Authors: Dan H Barouch; Louis J Picker
Journal: Nat Rev Microbiol Date: 2014-10-08 Impact factor: 60.633

4. Unabated adenovirus replication following activation of the cGAS/STING-dependent antiviral response in human cells.

Authors: Eric Lam; Erik Falck-Pedersen
Journal: J Virol Date: 2014-10-08 Impact factor: 5.103

5. Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.

Authors: Camilla Patrizia Hrycak; Sonja Windmann; Wibke Bayer
Journal: J Virol Date: 2019-10-15 Impact factor: 5.103

6. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors.

Authors: Pablo Penaloza-MacMaster; Nicholas M Provine; Joshua Ra; Erica N Borducchi; Anna McNally; Nathaniel L Simmons; Mark J Iampietro; Dan H Barouch
Journal: J Virol Date: 2012-11-14 Impact factor: 5.103

7. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.

Authors: Lindsey R Baden; Jinyan Liu; Hualin Li; Jennifer A Johnson; Stephen R Walsh; Jane A Kleinjan; Brian A Engelson; Lauren Peter; Peter Abbink; Danny A Milner; Kevin L Golden; Kyle L Viani; Matthew D Stachler; Benjamin J Chen; Maria G Pau; Mo Weijtens; Brittany R Carey; Caroline A Miller; Edith M Swann; Mark Wolff; Hayley Loblein; Michael S Seaman; Raphael Dolin; Dan H Barouch
Journal: J Infect Dis Date: 2014-08-26 Impact factor: 5.226